Advertisement

A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes

  • Raquel Estebainha
  • Raquel Goldhardt
  • Manuel FalcãoEmail author
Retina (R Goldhardt, Section Editor)
  • 3 Downloads
Part of the following topical collections:
  1. Topical Collection on Retina
  2. Topical Collection on Retina

Abstract

Purpose of Review

Fluocinolone acetonide is a synthetic fluorinated glucocorticoid. It has selective and potent agonist properties by binding to the cytosolic glucocorticoid receptor with high affinity; it is devoid of mineralocorticoid activity. Two extended-release (i.e., lasting up to 3 years) drug delivery systems containing fluocinolone acetonide (FAc) have been approved by the FDA for intravitreal use: Retisert® (Bausch&Lomb, NJ, USA) and Iluvien® (Alimera Sciences, Atlanta, USA). The former contains 0.59 mg of FAc, which is approved for the treatment of chronic non-infectious posterior segment uveitis. The latter contains a dose of 0.19 mg of FAc and is approved for the treatment of diabetic macular edema, and here we review the results published in the clinical literature relating to its use in the treatment of diabetic macular edema (DME).

Recent Findings

The 0.19-mg FAc implant (Iluvien®) is a new approved treatment approach for DME. It is a non-biodegradable implant that continuously releases a microdose of FAc into the vitreous cavity for up to 3 years. It is effective in chronic DME with the added value of decreasing the treatment burden of multiple intravitreal injections. Recently, clinical practice studies are reporting its efficacy and safety profile (intraocular pressure rise and cataract), as well as its use in clinical setting not included in clinical trial such as vitrectomized eyes.

Summary

The FAc implant has demonstrated in clinical practice results that mirror the results of the clinical trials efficacy wise. Regarding its safety profile, cataract is a common complication; however, intraocular pressure rises may be lower than the ones reported in trials. The implant has shown effectiveness in vitrectomized eyes. An increasing evidence of real-world studies has supported utility of the implant in DME patients. Its extended-release format for up to 3 years benefits the patient and carer as it means fewer injections and visits to the clinic.

Keywords

Diabetic macular edema Intravitreal corticosteroids Long-acting corticosteroids, diabetic retinopathy 

Notes

Funding Information

This manuscript received financial support the National Institutes of Health Center Core Grant (P30 EY014801), research to prevent blindness unrestricted grant.

Compliance with Ethical Standards

Conflict of Interest

Raquel Estebainha declares no potential conflicts of interest.

Raquel Goldhardt is section editor of the Retina section of Current Ophthalmology Reports.

Manuel Falcão has received travel grants from Alimera, Allergan, Bayer, and Novartis and received lecture honoraria from Alimera and Bayer.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;150218140025008.Google Scholar
  2. 2.
    Veritti D, Sarao V, Diplotti L, Samassa F, Lanzetta P. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Opin Pharmacother. 2017 Oct;18(14):1507–16.CrossRefGoogle Scholar
  3. 3.
    Syed YY. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): a review in diabetic macular edema. Drugs. 2017;77(5):575–83.CrossRefGoogle Scholar
  4. 4.
    Haritoglou C, Mayer W, Wolf A. Fluocinolone acetonide for the treatment of diabetic macular edema. Expert Rev Clin Pharmacol. 2016;9(3):367–74.  https://doi.org/10.1080/14656566.2017.1363182.CrossRefPubMedGoogle Scholar
  5. 5.
    Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64 Available from: http://care.diabetesjournals.org/cgi/doi/10.2337/dc11-1909.CrossRefGoogle Scholar
  6. 6.
    Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology. 1995;102(1):7–16.  https://doi.org/10.1016/S0161-6420(95)31052-4.CrossRefPubMedGoogle Scholar
  7. 7.
    Minassian D, Owens D, Reidy AMP. Diabetic macular oedema and related sight loss at first screening for eye disease. The Wales Diabetic Retinopathy Screening Service (WDRSS). UK Vision Strategy. 2010;3:2008.Google Scholar
  8. 8.
    Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema. Ophthalmol Therapy. 2016;5(1):95–104.CrossRefGoogle Scholar
  9. 9.
    Ferris FL, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl(August 1986)):452–61.CrossRefGoogle Scholar
  10. 10.
    Bandello F, Preziosa C, Querques G, Lattanzio R. Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic Res. 2014;52(2):89–96.CrossRefGoogle Scholar
  11. 11.
    Haritoglou C, Neubauer AS, Kernt M. Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema. Clin Ophthalmol. 2013;7:503–9 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3595182&tool=pmcentrez&rendertype=abstract.CrossRefGoogle Scholar
  12. 12.
    Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 2009;116(11):2175–2181.e1 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0161642009004102.CrossRefGoogle Scholar
  13. 13.
    Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54.CrossRefGoogle Scholar
  14. 14.
    Ross EL, Hutton DW, Stein JD, Bressler NM, Jampol LM, Glassman AR, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment. JAMA Ophthalmol. 2016;134(8):1–10.CrossRefGoogle Scholar
  15. 15.
    Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.  https://doi.org/10.1016/j.ophtha.2015.03.024.CrossRefGoogle Scholar
  16. 16.
    Saedon H, Anand A, Yang YC. Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature. Clin Ophthalmol. 2017;11:583–90.CrossRefGoogle Scholar
  17. 17.
    Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22.  https://doi.org/10.1016/j.ophtha.2013.02.034.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Calvo P, Abadia B, Ferreras A, Ruiz-Moreno O, Verdes G, Pablo LE. Diabetic macular edema: options for adjunct therapy. Drugs. 2015;75(13):1461–9.CrossRefGoogle Scholar
  19. 19.
    Elaraoud I, Quhill H, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema: 10 eyes with 12 months follow-up. Ophthalmol Therapy. 2016;5(1):105–9.CrossRefGoogle Scholar
  20. 20.
    Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–72.CrossRefGoogle Scholar
  21. 21.
    Daruich A, Matet A, Behar-Cohen F. Sustained-release steroids for the treatment of diabetic macular edema. Curr Diab Rep. 2015;15(11).Google Scholar
  22. 22.
    Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257–64.CrossRefGoogle Scholar
  23. 23.
    Nurözler Tabakcı B, Ünlü N. Corticosteroid treatment in diabetic macular edema. Türk Oftalmol Derg. 2017;47(3):156–60 Available from: http://cms.galenos.com.tr/FileIssue/6/1205/article/156-160-ing.pdf.CrossRefGoogle Scholar
  24. 24.
    Do D V., Shah SM, Sung JU, Haller JA, Nguyen QD. Persistent diabetic macular edema is associated with elevated hemoglobin A1c. Am J Ophthalmol. 2005 [cited 2018 Aug 22];139(4):620–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15808156.CrossRefGoogle Scholar
  25. 25.
    Hussain RM, Ciulla TA. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy. Expert Opin Biol Ther. 2016;16(3):365–74 Available from: http://www.tandfonline.com/doi/full/10.1517/14712598.2016.1131265.CrossRefGoogle Scholar
  26. 26.
    Falcao M. Diabetic retinopathy: understanding pathologic angiogenesis and exploring its treatment options. Open Circ Vasc J. 2012;3(1):30–42.CrossRefGoogle Scholar
  27. 27.
    Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19(April):1734–46 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3733907&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Stewart MW. Corticosteroid use for diabetic macular edema: old fad or new trend? Curr Diab Rep. 2012;12(4):364–75.CrossRefGoogle Scholar
  29. 29.
    Schwartz SG, Scott IU, Stewart MW, Flynn HW. Update on corticosteroids for diabetic macular edema. Clin Ophthalmol. 2016;10:1723–30.CrossRefGoogle Scholar
  30. 30.
    Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.  https://doi.org/10.1016/j.ophtha.2012.09.014.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pessoa B, Coelho J, Correia N, Ferreira N, Beirão M, Meireles A. Fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018 [cited 2018 Aug 23];59(2):68–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29248913.CrossRefGoogle Scholar
  32. 32.
    Meireles A, Goldsmith C, El-Ghrably I, Erginay A, Habib M, Pessoa B, et al. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy. Eye. 2017;31(5):684–90.  https://doi.org/10.1038/eye.2016.303.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393–1399.e3.  https://doi.org/10.1016/j.ophtha.2009.11.024.CrossRefPubMedGoogle Scholar
  34. 34.
    Campochiaro PA, Brown DM, Pearson A, Ciulla T, Boyer D, Holz FG, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0161642010013813.CrossRefGoogle Scholar
  35. 35.
    Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.  https://doi.org/10.1016/j.ophtha.2012.04.030.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wykoff CC, Chakravarthy U, Campochiaro PA, Bailey C, Green K, Cunha-Vaz J. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–9.  https://doi.org/10.1016/j.ophtha.2016.11.034.CrossRefPubMedGoogle Scholar
  37. 37.
    El-Ghrably I, Steel DHW, Habib M, Vaideanu-Collins D, Manvikar S, Hillier RJ. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 μg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357–62.CrossRefGoogle Scholar
  38. 38.
    Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien(R)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801–11.CrossRefGoogle Scholar
  39. 39.
    Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, Tsaloumas M, Quhill F, et al. Use of fluocinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16(1):3.CrossRefGoogle Scholar
  40. 40.
    Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J, Medisoft Audit Group. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye (Lond). 2017;31(12):1707–15.CrossRefGoogle Scholar
  41. 41.
    Chakravarthy U, Taylor SR, Koch FHJ, Castro de Sousa JP, Bailey C. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. Br J Ophthalmol. 2018 21 [cited 2018 Oct 6];bjophthalmol-2018-312284. Available from: http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2018-312284
  42. 42.
    Bertelmann T, Schulze S. Long-term follow-up of patient with diabetic macular edema receiving fluocinolone acetonide intravitreal implant. Ophthalmol Therapy. 2015;4(1):51–8 Available from: http://link.springer.com/10.1007/s40123-015-0028-0.CrossRefGoogle Scholar
  43. 43.
    Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 μg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33:33–43.  https://doi.org/10.1080/03007995.2017.1366662.CrossRefPubMedGoogle Scholar
  44. 44.
    Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 μg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33:5–17.  https://doi.org/10.1080/03007995.2017.1366645.CrossRefPubMedGoogle Scholar
  45. 45.
    Currie CJ, Holden SE, Berni E, Owens DR. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 μg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33:19–31.  https://doi.org/10.1080/03007995.2017.1366659.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Raquel Estebainha
    • 1
  • Raquel Goldhardt
    • 2
    • 3
  • Manuel Falcão
    • 4
    • 5
    Email author
  1. 1.Faculty of Medicine of the University of PortoPortoPortugal
  2. 2.Miami Veterans Administration Medical CenterMiamiUSA
  3. 3.Department of Ophthalmology, Bascom Palmer Eye InstituteUniversity of MiamiMiamiUSA
  4. 4.Department of Surgery and Physiology, Faculty of MedicineUniversity of PortoPortoPortugal
  5. 5.Department of OphthalmologyCentro Hospitalar Universitario S. JoãoPortoPortugal

Personalised recommendations